Nurix Therapeutics, Inc.

NasdaqGM:NRIX Lagerbericht

Marktkapitalisierung: US$1.3b

Nurix Therapeutics Management

Management Kriterienprüfungen 4/4

Nurix Therapeutics' CEO ist Arthur Sands , ernannt in Sep 2014, hat eine Amtszeit von 9.75 Jahren. Die jährliche Gesamtvergütung beträgt $4.36M , bestehend aus 13.5% Gehalt und 86.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.48% der Aktien des Unternehmens, im Wert von $4.71M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4 Jahre bzw. 3.8 Jahre.

Wichtige Informationen

Arthur Sands

Geschäftsführender

US$4.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts13.5%
Amtszeit als Geschäftsführer9.8yrs
Eigentum des Geschäftsführers0.5%
Durchschnittliche Amtszeit des Managements4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder3.8yrs

Jüngste Management Updates

Recent updates

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29
What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20
Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18
Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28
We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Mar 07
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Nurix: Advancing Targeted Protein Modulation Therapies

Nov 21

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

Nov 21
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn

Jul 24
We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn

Nurix Therapeutics appoints new operations chief

Jun 21

Nurix Therapeutics adds Clay Siegall to its board of directors

Jun 01

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Arthur Sands im Vergleich zu den Einnahmen von Nurix Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Feb 29 2024n/an/a

-US$145m

Nov 30 2023US$4mUS$591k

-US$144m

Aug 31 2023n/an/a

-US$149m

May 31 2023n/an/a

-US$157m

Feb 28 2023n/an/a

-US$179m

Nov 30 2022US$9mUS$572k

-US$180m

Aug 31 2022n/an/a

-US$171m

May 31 2022n/an/a

-US$154m

Feb 28 2022n/an/a

-US$135m

Nov 30 2021US$5mUS$539k

-US$117m

Aug 31 2021n/an/a

-US$99m

May 31 2021n/an/a

-US$89m

Feb 28 2021n/an/a

-US$63m

Nov 30 2020US$17mUS$521k

-US$43m

Aug 31 2020n/an/a

-US$37m

May 31 2020n/an/a

-US$21m

Feb 29 2020n/an/a

-US$24m

Nov 30 2019US$1mUS$474k

-US$22m

Vergütung im Vergleich zum Markt: ArthurDie Gesamtvergütung ($USD4.36M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD3.40M).

Entschädigung vs. Einkommen: ArthurDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Arthur Sands (62 yo)

9.8yrs

Amtszeit

US$4,363,120

Vergütung

Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Arthur Sands
CEO, President & Director9.8yrsUS$4.36m0.48%
$ 6.4m
Johannes Van Houte
Chief Financial Officer8.3yrsUS$1.61m0.075%
$ 1.0m
Gwenn Hansen
Chief Scientific Officer4yrsUS$1.63m0.062%
$ 826.4k
John Kuriyan
Founder & Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Michael Rapé
Founder & Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Arthur Weiss
Founder & Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Rita Kwong
Senior Accounting Managerno datakeine Datenkeine Daten
Pasit Phiasivongsa
Chief Technical Officerless than a yearkeine Datenkeine Daten
Christine Ring
Chief Legal Officer4.8yrsUS$1.65m0.031%
$ 414.1k
Eric Schlezinger
Chief People Officer1.8yrskeine Datenkeine Daten
Jason Kantor
Chief Business Officer3.9yrskeine Datenkeine Daten
Christopher Phelps
Senior VP & Head of Early Drug Discovery3.4yrskeine Datenkeine Daten

4.0yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: NRIXDas Führungsteam des Unternehmens gilt als erfahren (4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Arthur Sands
CEO, President & Director9.8yrsUS$4.36m0.48%
$ 6.4m
John Kuriyan
Founder & Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Michael Rapé
Founder & Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Arthur Weiss
Founder & Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Julia Gregory
Independent Chairman4.8yrsUS$238.29k0%
$ 0
Ronald Levy
Member of Medical Advisory Board1.4yrskeine Datenkeine Daten
Judith Reinsdorf
Independent Director2.7yrsUS$225.79k0%
$ 0
Roy Baynes
Member of Medical Advisory Boardno datakeine Datenkeine Daten
Lori Kunkel
Independent Director4.9yrsUS$228.29k0.084%
$ 1.1m
David Lacey
Independent Director8.2yrsUS$263.29k0.052%
$ 695.6k
Paul Silva
Independent Director2.7yrsUS$225.79k0%
$ 0
Edward Saltzman
Independent Director1.8yrsUS$223.29k0%
$ 0

3.8yrs

Durchschnittliche Betriebszugehörigkeit

67.5yo

Durchschnittliches Alter

Erfahrener Vorstand: NRIXDie Vorstandsmitglieder gelten als erfahren (3.7 Jahre durchschnittliche Amtszeit).